Kyverna Therapeutics is progressing toward filing its Biologics License Application (BLA) by Q4 2026 for a cell therapy targeting Stiff Person syndrome, a rare autoimmune disease with no current approved treatments. If successful, this would mark the first approved cell therapy for autoimmune diseases globally, positioning Kyverna as a pioneer in this field. The company highlighted its leadership in developing cell therapies for autoimmune conditions during the Morgan Stanley Global Healthcare Conference.
Kyverna Therapeutics, Inc. is the subject of this update. For readers following healthcare stocks, here is Pluang's market snapshot as of Sep 15, 2026 09:51 WIB: Among 91 priced US health-sector stocks, 73 rose and 18 fell today. Notable gainers include Twist Bioscience Corp (TWST) at USD 134.81 with a 5.97% increase, American Well Corp (AMWL) at USD 13.76 up 5.85%, and Summit Therapeutics Inc (SMMT) at USD 18.53 rising 5.58%.
An analyst from BMO Capital set a $67 price target for Devon Energy, suggesting a 40% upside from its current share price of around $48. The oil and gas producer has consistently beaten earnings estimates recently, showing strong financial health. Ho...
An investment of $10,000 in Marvell stock a decade ago has grown to approximately $206,000 today. Achieving the same growth again would require an annual earnings increase of 35%. This highlights Marvell's strong past performance and the challenge of...
Analyst Ivan Feinseth of Tigress Financial raised Amazon's price target from $315 to $385, reflecting a potential 50.8% upside from the current price of $255.37. The upgrade is driven by strong demand for Amazon Web Services (AWS), with much of its 2...
Omega Pacific Resources Ltd. has initiated a 5,000-metre drilling program at its Williams Gold Project in British Columbia's Toodoggone District following promising 2024 gold discoveries. The project targets gold and copper-gold porphyry deposits ami...
Ondo Finance has expanded into private markets with Ondo Private Markets, offering tokenized notes linked to the value of an unnamed pre-IPO AI company. Unlike buying shares, investors receive notes whose payouts depend on the company's liquidity eve...
